Premium
NK Cell immunotherapy for high‐risk neuroblastoma relapse after haploidentical HSCT
Author(s) -
Kanold Justyna,
Paillard Catherine,
Tchirkov Andrei,
Lang Peter,
Kelly Antony,
Halle Pascale,
Isfan Florentina,
Merlin Etienne,
Marabelle Aurelien,
Rochette Emmanuelle,
Deméocq François
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24030
Subject(s) - medicine , oncology , neuroblastoma , topotecan , immunotherapy , refractory (planetary science) , temozolomide , hematopoietic stem cell transplantation , chemotherapy , transplantation , cancer , genetics , physics , astrobiology , biology , cell culture
Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo‐HSCT) performed for the high‐risk neuroblastoma (NB). We describe a 6‐year‐old male with refractory NB who relapsed 22 months after haplo‐HSCT. A complete remission was obtained with a combination of immuno‐chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo‐graft provided via haplo‐NK cells and the immunogenic platform that haplo‐HSCT offers for future treatment. Our post‐relapse strategy shows that chemo‐ and bio‐treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739–742. © 2011 Wiley Periodicals, Inc.